Research progress of esophagogastric junction cancer in the 91st Annual Meeting of Japanese Gastric Cancer Association

Han Liang
DOI: https://doi.org/10.3760/cma.j.issn.1673-9752.2019.06.005
2019-01-01
Abstract:The 91st Annual Meeting of Japanese Gastric Cancer Association was held in Shizuoka,Japan from 26th February to 1st March,2019.In this article,the author reviewed the analyzed research progress of the esophagogastric junction EGJ cancer in this meeting.Epidemiological data show that in the past 30 years,the incidence of squamous cell carcinoma of the EGJ is gradually decreasing,and the incidence of adenocarcinoma of the esophagogastric junction (AEG) is gradually increasing.Due to the special anatomical position,endoscopic surgery for early EGJ cancer is more demanding.Perioperative therapy is the standard treatment in Europe,which is confirmed by many researches.There were many researches aimed to investigate objective efficacy of neoadjuvant chemoradiotherapy.A multicenter prospective randomized study co-sponsored by the Japanese Society of Gastric Cancer and Society of Esophageal Cancer has answered the controversial clinical question of surgical approach and extent of lymph node dissection for AEG.Reasonable reconstruction of digestive tract after proximal gastrectomy is challenging.The proximal gastric tube interposition has clinical rationality,and the transhiatal approach should be chosen for jejunal interposition and double tract reconstruction.The reconstruction of lower esophageal sphincter was achieved by Kamikawa method,however,its indication should be strictly controlled.
What problem does this paper attempt to address?